Aim: To evaluate the efficacy of intravitreal bevacizumab (IB) in the long-term control of subfoveal choroidal neovascularization (CNV) associated with angioid streaks (AS).
Methods: Patients with unilateral active CNV associated with AS were enrolled. Exclusion criteria were previous treatment for CNV and co-morbidity. Postoperative visual acuity was defined as a gain or loss of 2 or more lines of best-corrected visual acuity (BCVA).
Post-treatment CNV size was dichotomized into “increased”, if the CNV area had grown by ≥200 μm2, and “stable/reduced” if it had decreased by ≥200 μm2 or had not changed by more than 200 μm2. Patients were retreated if no further improvement or worsening was noted.
Results: Patients were 5 males and 6 females aged 33 to 58 years (mean 46.8±9.2 SD), who received a mean number of 3.5 IB treatments (±1.3; min: 2, max: 6). The mean retreatment interval was 3 months (±1.5; min: 1, max: 6). Mean follow-up duration was 23.8±2.9 months. At 20 months all patients had stable/reduced CNV size and stable/improved BCVA. Mean BCVA rose significantly from 0.28±0.2 at baseline to 0.56±0.29 at 20 months (p<0.0001).
Conclusion: IB is a promising tool for the long-term control of CNV in AS. Further studies are required to validate these findings.